Hyperleukocytosis from arsenic trioxide

descriptionPublicationkeyboard_double_arrow_right Article 25 Feb 2008 English Publisher:WileyJournal:Pediatric Blood & Cancer, volume 50, pages 1,265-1,267 (issn: 1545-5009, eissn: 1545-5017,

Copyright policy )

Authors: Michael, Levy; Marcia M, Wofford; Bayard L, Powell; Thomas W, McLean;

doi: 10.1002/pbc.21532

pmid: 18300308

Hyperleukocytosis from arsenic trioxide

- Summary
- Subjects
- Metrics

Abstract

AbstractWe report the case of a 14‐year‐old male treated with arsenic trioxide for recurrent acute promyelocytic leukemia. He developed hyperleukocytosis (WBC 111.6 × 109/L) which then resolved while continuing daily arsenic. Hyperleukocytosis without other complications may not be an indication for adding cytotoxic therapy or steroids, nor for discontinuing arsenic trioxide therapy in children. Pediatr Blood Cancer 2008;50:1265–1267. © 2008 Wiley‐Liss, Inc.

Related Organizations

Wake Forest University
United States

Keywords

Male, Adolescent, Arsenic Trioxide, Leukemia, Promyelocytic, Acute, Leukocytosis, Recurrence, Humans, Antineoplastic Agents, Oxides, Arsenicals

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	2
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average